SCHEMBL13290787

SCHEMBL13290787

COCCN(C)C(=O)c1ccc2oc(C(=O)Nc3ccc(Cl)cn3)c(NC(=O)[C@H]3CC[C@H](C(=O)N(C)CCN(C)C)CC3)c2n1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ F10 P00742 11/20 0.35
▸ TBK1 Q9UHD2 1/20 0.34
▸ DEGS1 O15121 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ F2 P00734 1/20 0.33
▸ HSD17B10 Q99714 2/20 0.33
▸ KDM4E B2RXH2 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ ALOX15 P16050 1/20 0.32
▸ TSHR P16473 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ USP30 Q70CQ3 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2949333 0.94 F10 (0.37) SMN1; SMN2F10TBK1DEGS1NPC1
SCHEMBL13290775 0.92 SMN1; SMN2 (0.38) SMN1; SMN2F10DEGS1NPC1RAB9A
SCHEMBL13290780 0.90 SMN1; SMN2 (0.39) SMN1; SMN2F10DEGS1NPC1RAB9A
SCHEMBL2943541 0.88 F10 (0.38) SMN1; SMN2F10TBK1F2TSHR
SCHEMBL13891910 0.88 F10 (0.38) SMN1; SMN2F10TBK1DEGS1NPC1
SCHEMBL13290967 0.88 SMN1; SMN2 (0.38) SMN1; SMN2F10DEGS1NPC1RAB9A
SCHEMBL4280986 0.88 F10 (0.38) SMN1; SMN2F10TBK1F2TSHR
SCHEMBL13290784 0.87 F10 (0.37) SMN1; SMN2F10TBK1F2
SCHEMBL13290957 0.87 SMN1; SMN2 (0.41) SMN1; SMN2F10DEGS1NPC1RAB9A
SCHEMBL13290963 0.86 SMN1; SMN2 (0.39) SMN1; SMN2F10DEGS1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US disclosed
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156803-A1 Condensed furan compounds F2, F12, F11 SMN1; SMN2 4447/4885F10 4/4885TBK1 2403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback